ARID1A deficiency activates OSM-STAT3 axis in endometrial cancer, creating vulnerability to JAK/STAT3 inhibition - PubMed
2 days ago
- #ARID1A
- #JAK-STAT3
- #endometrial-cancer
- ARID1A deficiency in endometrial cancer activates the OSM-STAT3 axis, making it vulnerable to JAK/STAT3 inhibition.
- A synthetic lethal drug screen identified JAK/STAT3 pathway as a therapeutic target in ARID1A-deficient endometrial cancer.
- ARID1A deficiency promotes transcription of Oncostatin M (OSM), leading to autocrine activation of JAK/STAT3 signaling and increased PLK1 levels.
- Elevated OSM levels in ARID1A-deficient endometrial cancer correlate with poor patient survival.
- Inhibition of the OSM-STAT3-PLK1 axis presents a new therapeutic approach for endometrial cancer with ARID1A loss.